Adenopathy, or lymphadenopathy, refers to abnormal enlargement of lymph nodes — the bean-shaped immune organs distributed in chains and clusters throughout the body that filter lymphatic fluid, trap pathogens and abnormal cells, and coordinate immune responses. Enlarged lymph nodes signal that the immune system is responding to something: this ranges from entirely benign reactive hyperplasia from a common infection to lymphoma or metastatic cancer requiring urgent treatment. The most important role of imaging in adenopathy is to characterize the distribution, morphology, and associated findings that point toward the underlying diagnosis.
Adenopathy is a downstream sign of many conditions evaluated throughout this conditions library. Malignant liver masses — particularly cholangiocarcinoma and hepatocellular carcinoma — spread to porta hepatis and celiac lymph nodes that are directly in the MRI field of view. Pancreatic cancer involves peripancreatic and retroperitoneal nodes as part of its early staging. Renal cell carcinoma spreads to para-aortic and paracaval nodes between the renal hilum and the diaphragm. Splenomegaly from lymphoma is frequently accompanied by retroperitoneal and mesenteric adenopathy visible on the same abdominal MRI. Biliary duct obstruction from portal adenopathy is an important and sometimes missed cause of obstructive jaundice. Comprehensive abdominal MRI evaluates all of these nodal stations simultaneously alongside the primary organ findings.
Causes
Infection.
Infection is the most common cause of adenopathy overall. Regional lymph nodes enlarge as they trap pathogens draining from the site of infection and mount an immune response — the enlargement is reactive and expected. Viral infections — Epstein-Barr virus (infectious mononucleosis), cytomegalovirus, HIV (which produces persistent generalized lymphadenopathy from chronic immune activation), and acute viral hepatitis — typically cause bilateral, relatively symmetric, soft, and tender lymphadenopathy. Bacterial infections produce more localized adenopathy that is often tender, warm, and erythematous — occasionally with suppuration (lymph node abscess requiring drainage). Mycobacterium tuberculosis (TB) is a particularly important cause of intra-abdominal and retroperitoneal adenopathy in endemic regions — TB nodes often undergo central necrosis producing a characteristic low-density center on CT and T2-hyperintense center with ring enhancement on MRI. Parasitic infections — toxoplasmosis, Chagas disease — and fungal infections including histoplasmosis cause systemic adenopathy in immunocompromised and endemic populations.
Inflammatory and autoimmune conditions.
Sarcoidosis — a systemic granulomatous disease of unknown etiology — classically causes bilateral hilar and mediastinal adenopathy, but abdominal involvement with hepatic granulomas, splenomegaly, and retroperitoneal adenopathy occurs in approximately 20–30% of cases. Sarcoid nodes are typically non-necrotic and may show homogeneous enhancement on MRI. Systemic lupus erythematosus (SLE) causes generalized lymphadenopathy during disease flares. Rheumatoid arthritis, Sjögren syndrome, and Castleman disease (a rare lymph node disorder with plasmacytic or multicentric giant lymph node hyperplasia) are additional inflammatory causes. Certain medications — phenytoin, allopurinol, captopril — can cause drug-induced serum sickness-like reactions with generalized adenopathy that resolves on drug discontinuation.
Malignancy.
Lymphoma — both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) — is the prototype malignant cause of adenopathy and is characterized by painless, progressive, non-tender nodal enlargement. HL spreads in a predictable, contiguous nodal pattern; NHL is more heterogeneous and often involves extranodal sites (bone marrow, liver, spleen). Metastatic adenopathy from solid tumors reaches lymph nodes through lymphatic channels draining the primary tumor site — abdominal nodal stations receive drainage from pancreas, liver, kidney, adrenal gland, colon, stomach, and retroperitoneum. The pattern of nodal involvement — porta hepatis, celiac, superior mesenteric, retroperitoneal, para-aortic — provides anatomic clues to the primary tumor site when staging an unknown primary.
Symptoms
Lymph nodes in superficial accessible locations — the neck, axillae, and inguinal regions — can often be felt as palpable lumps. The character of the palpable nodes provides important diagnostic information: tender, soft, mobile nodes suggest reactive or infectious adenopathy; hard, fixed, rubbery nodes suggest lymphoma or metastatic carcinoma. Intra-abdominal and retroperitoneal nodes are entirely silent unless they become large enough to cause mass effect — compressing the biliary system causing obstructive jaundice, compressing the ureter causing hydronephrosis, or displacing bowel causing partial obstruction.
The "B symptoms" of lymphoma — fever (>38°C), drenching night sweats, and unintentional weight loss of more than 10% of body weight over 6 months — are constitutional symptoms that indicate systemic disease and carry important prognostic significance. Their presence upgrades lymphoma stage and influences treatment intensity. Pruritus (generalized itching without a rash) is a recognized constitutional symptom of Hodgkin lymphoma related to cytokine release. Sudden painful enlargement of previously stable nodes suggests either superimposed infection or rapid malignant proliferation — both warrant urgent evaluation.
Diagnosis
Evaluation begins with clinical assessment — duration, pace of growth, tenderness, associated symptoms, travel history, exposures, and prior malignancy. Laboratory tests assess for infection markers (CBC, ESR, CRP, monospot, HIV, CMV), autoimmune markers (ANA, anti-dsDNA, RF), and tumor markers (LDH — elevated in lymphoma and aggressive malignancies; CA 19-9 for pancreatic/biliary primaries; CEA for colorectal). Peripheral blood smear may identify abnormal lymphocytes (lymphoma, CLL).
An MRI of the abdomen is the most detailed noninvasive imaging study for abdominal and retroperitoneal adenopathy, providing both anatomic characterization and MRI-specific tissue features unavailable on CT. On MRI, normal lymph nodes are small (short-axis diameter under 10 mm in most abdominal stations), oval, homogeneous, and preserve a fatty hilum. Pathologically enlarged nodes lose the fatty hilum, become round (rather than oval), and may show central necrosis (low T1, high T2 center with rim enhancement — characteristic of TB and metastatic squamous cell carcinoma), diffuse heterogeneous enhancement (lymphoma), or restricted diffusion on DWI (the most sensitive MRI feature for malignant adenopathy — restricted diffusion with low ADC values reflects the dense cellular packing of malignant nodes). The distribution pattern is diagnostically important: mesenteric adenopathy in a "sandwich sign" (mesenteric fat sandwiched between masses of enlarged nodes) is characteristic of lymphoma; retroperitoneal para-aortic adenopathy in a patient with a testicular mass or renal tumor suggests metastatic germ cell tumor or RCC. PET-CT adds functional metabolic information — FDG-avid nodes indicate active cellular metabolism and distinguish metabolically active (malignant or inflammatory) from inactive (treated or fibrotic) nodal disease. Lymph node biopsy — excisional, core-needle, or EUS-guided fine-needle aspiration — provides histologic diagnosis when imaging alone cannot determine etiology.
Classification
Adenopathy is classified by distribution, morphology, and underlying etiology.
- Localized adenopathy: Enlargement confined to a single nodal region; most often from local infection, regional skin or soft tissue inflammation, or regional tumor drainage. Key diagnostic question: what does this nodal station drain?
- Regional adenopathy: Involvement of multiple nodal stations within one body region (e.g., multiple abdominal stations); suggests regional disease spread from a primary process in that territory.
- Generalized adenopathy: Two or more non-contiguous nodal regions involved; strongly suggests systemic disease — viral infection (EBV, HIV), autoimmune disease (SLE, sarcoidosis), or hematologic malignancy (lymphoma, CLL).
- Morphologic features on MRI: Benign-appearing — oval shape, preserved fatty hilum, homogeneous signal, no restricted diffusion, short-axis <10 mm. Malignant-appearing — round shape, lost fatty hilum, heterogeneous or necrotic center, restricted diffusion (low ADC), short-axis >15 mm, or matted/confluent nodal masses.
Treatments
Treatment is directed at the underlying cause — adenopathy itself is a sign, not a diagnosis.
Infectious adenopathy: Bacterial adenopathy responds to appropriate antibiotics targeting the responsible organism. Suppurative (abscess-forming) nodes require incision and drainage in addition to antibiotics. TB adenopathy responds to standard anti-tuberculosis regimens (RIPE therapy for 6 months) — nodes may enlarge paradoxically during the first weeks of treatment before ultimately shrinking. Viral adenopathy is managed supportively — nodes typically resolve over 2–6 weeks as the immune response clears the infection. HIV-related adenopathy is managed with antiretroviral therapy.
Inflammatory and autoimmune adenopathy.
Sarcoidosis-related adenopathy is managed with corticosteroids when symptomatic or when organ function is threatened — adenopathy typically responds within weeks of starting therapy. Lupus and rheumatoid arthritis adenopathy is controlled through treatment of the underlying disease with immunosuppressive and disease-modifying therapies. Castleman disease — particularly the multicentric HHV-8-associated form — is treated with rituximab, siltuximab, or tocilizumab targeting IL-6 signaling, which drives the plasmacytic proliferation.
Lymphoma.
Treatment depends on lymphoma type and stage. Hodgkin lymphoma is one of the most curable cancers — ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) achieves cure in over 85% of patients with Stage I–II disease; advanced stages benefit from escalated BEACOPP or brentuximab vedotin-based regimens. Diffuse large B-cell lymphoma (DLBCL) — the most common NHL — is treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with curative intent in most patients. Indolent lymphomas (follicular, marginal zone) are often observed when asymptomatic. CAR-T cell therapy has transformed outcomes for relapsed/refractory DLBCL.
Metastatic adenopathy.
Treatment of nodal metastases is integrated into the management of the primary cancer — staging determines whether nodal dissection (lymphadenectomy), radiation, systemic therapy, or a combination is appropriate. For some cancers (colorectal, gastric, pancreatic), complete regional lymphadenectomy at the time of primary tumor resection is standard. For others (RCC, HCC), nodal metastases indicate Stage III–IV disease requiring systemic therapy. Targeted therapy and immunotherapy increasingly achieve durable nodal responses in lymphoma and solid tumor metastases that previously required surgery or radiation.
Observation.
Small, reactive-appearing abdominal nodes under 10 mm in short axis with no concerning MRI features, identified incidentally in a patient without known malignancy, are typically observed with follow-up imaging in 3–6 months to confirm resolution or stability. Persistent or growing nodes despite a reasonable observation period warrant tissue sampling.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.